BeiGene (BGNE) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions recommending an extended authorization for Tevimbra (tislelizumab) in gastric or gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
The recommendations were based on two clinical trials showing that the drug, in combination with chemotherapy, "improved survival compared to treatment with a placebo plus chemotherapy," said Florian Lordick, director and professor of oncology at the University Cancer Center in Leipzig.
BeiGene shares were 0.5% higher in recent premarket trading.
Price: 220.00, Change: +1.03, Percent Change: +0.47
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。